恐水病바이러스백신제조에 關한 硏究

Kyung‐Ho Kim, 최헌 · Journal of Bacteriology and Virology · 1972

Man occasionally develops paralytic complications following the repeated injection of rabbit brain rabies vaccine during the course of the treatment for rabies. In the last few months we have experimented with an antirabies vaccine produced from suckling mice and suckling rats. The reason for selecting suckling mice and rats, which are highly susceptible to rabies virus. The mice and rats were inoculated rabies fixed virus when they were 3 to 7 days old and their brains were harvested 4 to 5 days later when the rabies paralysis were cempletely appeared. Virucidal action of Beta-Propiolactone: Doubled dilutions of Beta-Propiolactone were added to a series of four 100ml amounts of virus suspension. Final concentrations of Beta-Propiolactone in the virus suspension were from 1:1000 to 1:8000 After refrigeration of the suspension at 4C for 24 hours, dilutions of each virus suspension were injected intracerebrally into groups of five mice to determine the titer of inactivation. As seen in the table 1, it is evident that concentration of Beta Propiolactone of 1:4000 killed the virus and 1:8000 concentration failed to do so. Thus it was demonstrated that preparation of killed antirabies vaccine could be attempted with concentration of Beta propiolactone up to 1:4000 but not with concentration of 1:8000 as weaker. Immunizing Potency: Two kinds of rabies vaccine (suckling mice and suckling rats sources) were used for vaccinating mice as a vaccine potency test according to the National Institute of Health test method. It was shown that the immunized mice protected more than mouse LDgp 10 4.2 for rat brain vaccine and mouse Ldso 10 for the mouse brain vaccine against challenge virus (Table 2). General safety test: Body weigh 300g healthy guinea pigs were used for general safety test. Each guinea pig was received 5ml of final mouse brain vaccine intraperitoneally and observed 14 days. The guinea pigs were normal during the observation period (Fig.1). Further immunological and pathological experiments are needed before human trial.

Cited by 0 works.

Authors